View of Semaglutide (Rybelsus) | Canadian Journal of Health Technologies Return to Article Details Semaglutide (Rybelsus)
3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib (11, 62)
PlexusDx compounded formulations offer dose flexibility and provider customization to match your clinical and genetic context
Only qualified research professionals should handle this product
Lo Faro, V
Making sure the medication doesnt come into direct contact with ice or cold packs, which could freeze it